Leerink Partnrs Issues Pessimistic Outlook for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for Alnylam Pharmaceuticals in a report released on Tuesday, October 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company will post earnings per share of $0.03 for the quarter, down from their previous forecast of $0.38. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q4 2025 earnings at $0.81 EPS and FY2025 earnings at ($0.10) EPS.

Several other research firms have also weighed in on ALNY. Raymond James Financial assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price objective on the stock. Royal Bank Of Canada increased their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, September 19th. Oppenheimer upgraded Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 target price for the company in a research report on Monday, August 4th. Evercore ISI increased their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research report on Thursday, September 11th. Finally, The Goldman Sachs Group increased their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a research report on Tuesday, September 16th. Twenty-four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $457.08.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $481.07 on Thursday. The stock’s 50-day simple moving average is $455.04 and its 200 day simple moving average is $350.64. The firm has a market capitalization of $63.06 billion, a PE ratio of -194.77 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $488.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s revenue was up 17.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $27,000. Bessemer Group Inc. increased its holdings in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals in the second quarter worth approximately $30,000. Elevation Point Wealth Partners LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter worth approximately $37,000. Finally, Hilltop National Bank bought a new stake in Alnylam Pharmaceuticals in the third quarter worth approximately $41,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 31,448 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares in the company, valued at $397,724.38. This trade represents a 97.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the transaction, the executive vice president owned 54,052 shares of the company’s stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock valued at $44,160,261 over the last ninety days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.